<DOC>
	<DOCNO>NCT00358384</DOCNO>
	<brief_summary>This study exploratory study evaluate effectiveness , safety tolerability three concentration GW786034 ointment follow treatment small area stable psoriatic plaque . Dosing proceed use microplaque approach , small volume ointment apply full occlusion representative psoriatic plaque . The effectiveness topical GW786034 treatment control explored use visual intensity assessment addition dermal image histological surrogate disease activity .</brief_summary>
	<brief_title>Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion criterion : Stable ( 23 month ) chronic plaque psoriasis cover great 5 % body surface area ( determine PASI palm method ) . Other chronic plaque psoriasis , subject health ambulatory . Women eligible enter study nonchildbearing potential ( i.e . physiologically incapable become pregnant , include female postmenopausal surgically sterile ) . Must least two clinically similar lesion follow characteristic deem dermatologist : Moderate severe elevation ( thickness ) , erythema , scale ( total score least 6 target lesion , assess use 04 PASI score ) . Located trunk , buttock , thigh upper arm . Are sufficient size allow application three occlusive patch . Exclusion criterion : Guttate , erythrodermic , pustular psoriasis . Psoriasis spontaneously improve . Have psoriasis unresponsive adequately dose ( &gt; 10 week ) cyclosporine . Any systemic disorder active skin disease ( psoriasis ) subject present scar , mole , tattoo , body piercings , sunburn test area . History congestive heart failure ( NYHA Class 3 4 ) , myocardial infarction , coronary artery bypass graft , percutaneous transluminal balloon angioplasty , cerebrovascular accident , chronic intermittent oedema . Blood pressure great 150mmHg systolic /or 95mmHg diastolic follow triplicate measurement take 5 minute apart . Presence unstable severe angina coronary insufficiency . Uncontrolled bacterial , viral , fungal infection . Congenital acquire immunodeficiency . History malignancy within last five year , except surgically cure skin carcinoma cervical dysplasia ( CIN III ) . An unwillingness male subject use condom/spermicide addition female partner use another form contraception woman could become pregnant time first dose study medication 5 halflives drug elapse follow removal last dose study medication . An unwillingness male subject abstain sexual intercourse pregnant lactate woman time first dose study medication five halflives 5 day ( whichever longer ) follow removal last dose study medication . Prolonged exposure sun ( tan bed ) study . Systemic antipsoriasis therapy , include limited : acitretin , cyclosporine , isotretinoin , infliximab , entercept , alefacept , oral steroid psoralen 4 week prior first dose study medication throughout study . Concomitant use phototherapy photochemotherapy . Concomitant use lithium , antimalarial , interferon . Systemic betablockers permit provide dose stable four week baseline remain stable throughout study . Concomitant use antiarthritis therapy know propensity hepatotoxicity ( i.e . diclofenac , gold , Dpenicillamine , leflunomide ) . Use topical intralesional treatment psoriasis ( e.g . mid highpotency topical corticosteroid ) within 2 week prior Day 1 throughout study , except class VI VII topical steroid treatment ( Desonide , 2.5 % hydrocortisone ) allow face . Concomitant use nondrug therapy ( i.e . herbal product alternative therapy ) psoriasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>tolerability</keyword>
	<keyword>safety</keyword>
	<keyword>angiogenesis</keyword>
	<keyword>vascular endothelial growth factor</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>microplaque</keyword>
	<keyword>VEGF</keyword>
	<keyword>GW786034</keyword>
</DOC>